Time on study and response duration* per investigator assessment. Patients with rrCLL (A), rrDLBCL (B), and rrMM (C). CR, complete response; PR, partial response. *Tumor response as assessed by investigator review according to International Workshop on CLL guidelines (2008) for the rrCLL cohort, revised International Working Group response criteria for malignant lymphoma (2007) for the rrDLBCL cohort, and International Myeloma Working Group Uniform Response Criteria (2006) for the rrMM cohort.